



## Canadian authorities grant product approval for Intercell's Vaccine to prevent Japanese Encephalitis

**Vienna, Austria, October 30, 2009** – Intercell AG (VSE: ICLL) today announced that the Health Canada granted product approval for IXIARO®, the company's vaccine to prevent Japanese Encephalitis (JE).

This decision of the Canadian authorities represents another important milestone for the product's global reach. Intercell's vaccine to prevent Japanese Encephalitis has already been successfully approved and launched in the USA, Europe and Australia.

"We are very pleased that IXIARO is now also approved by the Canadian authorities. This reflects another step in growing our IXIARO business by supplying this important product to travelers", states Gerd Zettlmeissl, Chief Executive Officer of Intercell.

Intercell's Japanese Encephalitis vaccine will be available for the Canadian market by the end of the year and will be distributed and marketed to travel clinics by Novartis Pharmaceuticals Canada Inc. and to the military personnel by Intercell.

IXIARO is a purified, inactivated product for active immunization against infection by the Japanese Encephalitis Virus. IXIARO is manufactured at Intercell's proprietary manufacturing facility in Scotland and is prepared using tissue culture rather than live organisms.

### About Japanese Encephalitis

Japanese Encephalitis (JE) is a deadly infectious disease found mainly in Asia. Approximately 30,000 to 50,000 cases of JE are reported in Asia each year, and the actual number of cases are likely much higher due to underreporting in rural areas. JE is fatal in approximately 30 percent of those who show symptoms and leaves half of survivors with permanent brain damage. As there is no specific treatment for JE, vaccination is the only effective protection for the millions of travelers and military personnel who live in or travel to areas where the virus circulates.

### About IXIARO

Intercell's novel Japanese Encephalitis vaccine is a purified, inactivated vaccine for active immunization of adults against the Japanese Encephalitis virus. The vaccine was developed under a Collaborative Research and Development Agreement with the Walter Reed Army Institute of Research, a biomedical research laboratory for the U.S. Department of Defense.

Intercell's Phase III trials for IXIARO found that the vaccine demonstrated immunogenicity against Japanese Encephalitis and an overall clinical safety profile similar to the control arm, combined with an excellent local tolerability profile. These data were published in The Lancet in December 2007:

- » The immunogenicity was comparable to that of the U.S. licensed product, JE-VAX®.
- » Intercell's vaccine demonstrated an overall clinical safety profile similar to the control arm.





» Further, Intercell's Japanese Encephalitis vaccine had a more favorable local tolerability profile in the head-to-head study with JE-VAX®.

Please refer to the Product / Prescribing information (PI) / Medication Guide approved in your respective countries for complete information including safety about this vaccine.

### **About Intercell AG**

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the Company's first product on the market.

The Company's technology platforms include an antigen-discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, and Sanofi Pasteur.

The Company's pipeline includes a Travelers' Diarrhea Vaccine Patch (Phase III), a Pseudomonas vaccine candidate (Phase II), a Vaccine Enhancement Patch to prevent Pandemic Influenza in combination with an injected vaccine (Phase II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In addition, three other products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL" (U.S. level one ADR symbol "INRLY").

For more information, please visit: [www.intercell.com](http://www.intercell.com)

### **Contact**

#### **Intercell AG**

Lucia Malfent

Global Head of Corporate Communications

Campus Vienna Biocenter 3, A-1030 Vienna

P: +43-1-20620-1303

Mail to: [LMalfent@intercell.com](mailto:LMalfent@intercell.com)

*This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*